Pfizer company name on a building
Drug manufacturer Pfizer stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz.

News Alert

Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals

Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.

Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer also is ending its policy exemption for hospitals’ wholly owned contract pharmacies. These will not be able anymore to separately receive 340B-purchaed Xeljanz on a bill to / ship to basis.

Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products. Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer […]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer